|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US7744877B2
(en)
*
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
WO2001060397A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
|
PT1974747E
(pt)
*
|
1998-08-11 |
2012-09-05 |
Biogen Idec Inc |
Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
|
MXPA01004649A
(es)
*
|
1998-11-09 |
2002-05-06 |
Idec Pharma Corp |
Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
|
|
ES2351149T3
(es)
*
|
1998-11-09 |
2011-02-01 |
Biogen Idec Inc. |
Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
|
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
|
AU766981B2
(en)
*
|
1999-04-20 |
2003-10-30 |
Ao Technology Ag |
Device for the percutaneous obtainment of 3D-coordinates on the surface of a human or animal organ
|
|
IL146005A0
(en)
|
1999-05-07 |
2002-07-25 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7527787B2
(en)
*
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
DE60042785D1
(de)
*
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
|
EP1216056A1
(en)
*
|
1999-07-12 |
2002-06-26 |
Genentech Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
US20020006404A1
(en)
*
|
1999-11-08 |
2002-01-17 |
Idec Pharmaceuticals Corporation |
Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
|
JP2003521903A
(ja)
*
|
2000-01-25 |
2003-07-22 |
ハイセック,インコーポレーテッド |
Cd84様ポリペプチドおよびポリヌクレオチドに関する方法と材料
|
|
EP1283722A1
(en)
*
|
2000-03-31 |
2003-02-19 |
Idec Pharmaceuticals Corporation |
Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
|
|
AU6836301A
(en)
*
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
EP1296714B1
(en)
*
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
WO2002022212A2
(en)
*
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceuticals Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
|
RU2287534C2
(ru)
|
2000-10-20 |
2006-11-20 |
Тугаи Сейяку Кабусики Кайся |
Деградированное антитело, являющееся агонистом tpo
|
|
AU2002213357A1
(en)
*
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
|
WO2002057316A1
(en)
*
|
2000-12-28 |
2002-07-25 |
Kirin Beer Kabushiki Kaisha |
Novel monoclonal antibody
|
|
CN101555283B
(zh)
*
|
2001-01-17 |
2012-03-21 |
生物权威国际有限公司 |
针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
BR0206985A
(pt)
*
|
2001-01-29 |
2005-04-19 |
Idec Pharma Corp |
Anticorpos modificados e métodos de uso
|
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
DK1392359T4
(da)
*
|
2001-05-11 |
2013-06-10 |
Ludwig Inst For Cancer Res Ltd |
Specifikke bindingsproteiner og deres anvendelser.
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
CN1511041A
(zh)
*
|
2001-05-17 |
2004-07-07 |
������ҩ������˾ |
利用抑制cd21的药剂治疗抗体介导的病变的方法
|
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
TACIs 및 BR3 폴리펩티드 및 이의 용도
|
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
|
|
US7355012B2
(en)
|
2001-09-26 |
2008-04-08 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
|
|
CA2476555A1
(en)
*
|
2002-02-14 |
2003-08-21 |
Nuvelo, Inc. |
Methods of therapy and diagnosis
|
|
EP1476120B1
(en)
|
2002-02-21 |
2010-09-29 |
Duke University |
Treatment methods using anti-cd22 antibodies
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8491896B2
(en)
*
|
2002-06-14 |
2013-07-23 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8435529B2
(en)
|
2002-06-14 |
2013-05-07 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
KR101017732B1
(ko)
*
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-cd74 항체 및 그 이용방법
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
|
US6991653B2
(en)
*
|
2002-03-21 |
2006-01-31 |
Sdgi Holdings, Inc. |
Vertebral body and disc space replacement devices
|
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
|
AU2003241313A1
(en)
*
|
2002-04-23 |
2003-11-10 |
Roger Williams Hospital |
Compositions and methods for stem cell delivery
|
|
BR122019027966B8
(pt)
*
|
2002-05-02 |
2021-07-27 |
Wyeth Corp |
conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
|
|
CA2487692A1
(en)
*
|
2002-05-29 |
2003-12-11 |
Immunomedics, Inc. |
Methods and compositions for radioimmunotherapy of brain and cns tumors
|
|
WO2003106497A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Immunomedics, Inc. |
Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
|
|
US8821868B2
(en)
|
2002-06-14 |
2014-09-02 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
US9599619B2
(en)
|
2002-06-14 |
2017-03-21 |
Immunomedics, Inc. |
Anti-pancreatic cancer antibodies
|
|
ES2524767T3
(es)
*
|
2002-06-14 |
2014-12-12 |
Immunomedics, Inc. |
Anticuerpo monoclonal humanizado HPAM4
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
BR0313033A
(pt)
*
|
2002-07-25 |
2007-07-10 |
Genentech Inc |
anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
US20090217404A1
(en)
*
|
2002-09-27 |
2009-08-27 |
Lowe Scott W |
Cell-based RNA interference and related methods and compositions
|
|
US8158385B2
(en)
|
2002-10-11 |
2012-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death-inducing agent
|
|
KR100944575B1
(ko)
*
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US20040120949A1
(en)
*
|
2002-11-08 |
2004-06-24 |
Boehringer Ingelheim International Gmbh |
Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
|
|
AU2003291002A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
NZ561600A
(en)
|
2002-11-19 |
2009-04-30 |
Clluone Therapeutics As |
Methods and kits for diagnosing and treating B-cell chronic lymphocytic leukemia (B-CLL)
|
|
US8420086B2
(en)
*
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
HUE035898T2
(en)
*
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US20090186839A1
(en)
*
|
2003-02-17 |
2009-07-23 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in chemoresistance
|
|
EP1599573B1
(en)
*
|
2003-02-17 |
2013-06-19 |
Cold Spring Harbor Laboratory |
Model for studying the role of genes in tumor resistance to chemotherapy
|
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
|
EP1609803A4
(en)
*
|
2003-03-31 |
2006-05-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODY AGAINST CD22 AND APPLICATIONS THEREOF
|
|
ME00426B
(me)
*
|
2003-04-09 |
2011-10-10 |
Genentech Inc |
Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
|
KR101351122B1
(ko)
*
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Cd20-특이적 항체 및 이를 이용한 방법
|
|
KR20060080535A
(ko)
*
|
2003-05-14 |
2006-07-10 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
ES2537738T3
(es)
*
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
US9005613B2
(en)
|
2003-06-16 |
2015-04-14 |
Immunomedics, Inc. |
Anti-mucin antibodies for early detection and treatment of pancreatic cancer
|
|
EP2256106B1
(en)
|
2003-07-22 |
2015-05-06 |
Astex Therapeutics Limited |
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
|
WO2005017529A1
(en)
*
|
2003-07-29 |
2005-02-24 |
Genentech, Inc. |
Assay for human anti cd20 antibodies and uses therefor
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
JP4733635B2
(ja)
*
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗cd19抗体
|
|
CA2534898A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
EP1660129A2
(en)
*
|
2003-08-29 |
2006-05-31 |
Genentech, Inc. |
Anti-cd20 therapy of ocular disorders
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
SG148161A1
(en)
*
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
|
DE602004029934D1
(de)
|
2003-12-04 |
2010-12-16 |
Kyowa Hakko Kirin Co Ltd |
Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
|
|
AU2004303848A1
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of CD20 in transplant rejection
|
|
JP2007514787A
(ja)
*
|
2003-12-19 |
2007-06-07 |
ジェネンテック・インコーポレーテッド |
自己免疫疾患の治療におけるcd20の検出
|
|
ES2689328T3
(es)
|
2004-01-07 |
2018-11-13 |
Novartis Vaccines And Diagnostics, Inc. |
Anticuerpo monoclonal M-CSF-específico y usos del mismo
|
|
JPWO2005075640A1
(ja)
*
|
2004-02-10 |
2008-01-10 |
学校法人日本大学 |
イヌcd20遺伝子
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8491914B2
(en)
*
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US20110171126A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
RU2006140377A
(ru)
*
|
2004-04-16 |
2008-05-27 |
Дженентек, Инк. (Us) |
Способ усиления уничтожения в-клеток
|
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
|
EP1740946B1
(en)
*
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
RU2006142857A
(ru)
*
|
2004-05-05 |
2008-06-10 |
Дженентек, Инк. (Us) |
Профилактика аутоиммунного заболевания
|
|
EP1751187A2
(en)
*
|
2004-05-28 |
2007-02-14 |
Idexx Laboratories, Inc. |
Canine cd20 compositions
|
|
JP2008501706A
(ja)
*
|
2004-06-04 |
2008-01-24 |
ジェネンテック・インコーポレーテッド |
疾患の治療方法
|
|
SG183012A1
(en)
*
|
2004-06-04 |
2012-08-30 |
Genentech Inc |
Method for treating multiple sclerosis
|
|
US20060062787A1
(en)
*
|
2004-07-22 |
2006-03-23 |
Genentech, Inc. |
Method for treating Sjogren's syndrome
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
KR20070041781A
(ko)
*
|
2004-08-11 |
2007-04-19 |
트루비온 파마슈티칼스, 인코포레이티드 |
결합 도메인 융합 단백질
|
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
|
CN101087807A
(zh)
*
|
2004-10-05 |
2007-12-12 |
健泰科生物技术公司 |
治疗血管炎的方法
|
|
US8420783B2
(en)
*
|
2004-12-08 |
2013-04-16 |
Immunomedics, Inc. |
Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
|
|
US8137907B2
(en)
*
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
|
EP1846432A4
(en)
*
|
2005-01-12 |
2008-11-19 |
Proteonova Inc |
METHOD FOR PRODUCING TARGETED THERAPEUTIC AGENTS
|
|
US10206998B2
(en)
|
2005-01-12 |
2019-02-19 |
Proteonova, Inc. |
Modular targeted therapeutic agents and methods of making same
|
|
US20060188495A1
(en)
*
|
2005-01-13 |
2006-08-24 |
Genentech, Inc. |
Treatment method
|
|
WO2006077425A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
EP1845974A1
(en)
*
|
2005-01-21 |
2007-10-24 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
EP1845973B1
(en)
*
|
2005-01-21 |
2015-08-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
PT1853718E
(pt)
*
|
2005-02-15 |
2015-11-12 |
Univ Duke |
Anticorpos anti-cd19 e usos em oncologia
|
|
US20060263357A1
(en)
*
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
|
US8444973B2
(en)
*
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US20080171067A1
(en)
*
|
2007-01-17 |
2008-07-17 |
Immunomedics, Inc. |
Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
CA2607475A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Genentech, Inc. |
Method for treating dementia or alzheimer's disease with a cd20 antibody
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
US7601335B2
(en)
*
|
2005-05-20 |
2009-10-13 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
|
WO2007053184A2
(en)
*
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
|
EP1904101A4
(en)
*
|
2005-06-08 |
2011-06-15 |
Univ Duke |
ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
|
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
sc(Fv)2を含有する医薬組成物
|
|
WO2007002223A2
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
|
AU2006272555B2
(en)
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
WO2007014238A2
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
Single dose use of cd20-specific binding molecules
|
|
EP2277916A3
(en)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Use of antibody to M-CSF
|
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
WO2007053524A2
(en)
*
|
2005-10-28 |
2007-05-10 |
The Florida International University Board Of Trustees |
Horse: human chimeric antibodies
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
*
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
EP2674440B1
(en)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
AU2007223903B2
(en)
|
2006-03-06 |
2013-09-05 |
Medimmune, Llc |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
|
US20090220416A1
(en)
*
|
2006-05-03 |
2009-09-03 |
Sydney Welt |
Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
|
|
CA2651152A1
(en)
*
|
2006-05-05 |
2007-11-15 |
Astex Therapeutics Limited |
4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
CN105837690A
(zh)
*
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
|
RU2009107707A
(ru)
|
2006-08-04 |
2010-09-10 |
Новартис АГ (CH) |
СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
|
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
|
US8323653B2
(en)
|
2006-09-08 |
2012-12-04 |
Medimmune, Llc |
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US20100036101A1
(en)
*
|
2006-10-10 |
2010-02-11 |
Angus Gidley-Baird |
Antibodies against non functional p2x7 receptor
|
|
WO2008043145A1
(en)
*
|
2006-10-10 |
2008-04-17 |
Biosceptre International Limited |
Hybridomas producing antibodies against non functional p2x7 receptor
|
|
SG177168A1
(en)
|
2006-12-01 |
2012-01-30 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
PE20130588A1
(es)
|
2007-02-02 |
2013-05-21 |
Amgen Inc |
Hepcidina, antagonistas de la hepcidina y metodos de uso
|
|
JP2010517583A
(ja)
|
2007-02-12 |
2010-05-27 |
プロテオノヴァ、 インコーポレイテッド |
mRNAに連結された可溶性ランダムポリペプチドのライブラリーの生成
|
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
|
NZ601583A
(en)
*
|
2007-05-21 |
2013-08-30 |
Bristol Myers Squibb Co |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
DK2164514T3
(en)
*
|
2007-05-21 |
2017-02-27 |
Alderbio Holdings Llc |
Antibodies to IL-6 and its use
|
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
EP2586788B1
(en)
|
2007-07-09 |
2017-11-29 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
|
JP5532486B2
(ja)
*
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
|
WO2009033234A1
(en)
|
2007-09-14 |
2009-03-19 |
Biosceptre International Limited |
Purinergic (p2x) receptors in extra-cellular body fluid
|
|
JP5670192B2
(ja)
|
2007-09-14 |
2015-02-18 |
バイオセプター・インターナショナル・リミテッド |
新規p2x7エピトープ
|
|
DK2233149T3
(en)
|
2007-10-16 |
2016-05-17 |
Zymogenetics Inc |
COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
|
|
CN101903403B
(zh)
|
2007-10-19 |
2016-03-16 |
西雅图基因公司 |
Cd19结合剂及其应用
|
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
EP2803675A3
(en)
|
2008-01-25 |
2014-12-24 |
Amgen, Inc |
Ferroportin antibodies and methods of use
|
|
WO2009124109A1
(en)
*
|
2008-04-04 |
2009-10-08 |
The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services |
Human monoclonal antibodies specific for cd22
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
WO2009139822A1
(en)
|
2008-05-01 |
2009-11-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
|
AU2009266430B2
(en)
|
2008-07-04 |
2014-08-14 |
Biosceptre International Limited |
Anti- P2X7 peptides and epitopes
|
|
WO2010022225A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
EP2331579B1
(en)
*
|
2008-09-04 |
2017-07-05 |
Vet Therapeutics, Inc. |
Monoclonal antibodies
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
WO2010051215A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Proteonova, Inc. |
Methods for making hiv vaccines and related compositions
|
|
US8323649B2
(en)
*
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
WO2010093450A2
(en)
|
2009-02-11 |
2010-08-19 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
WO2010110838A2
(en)
*
|
2009-03-25 |
2010-09-30 |
Vet Therapeutics Inc. |
Antibody constant domain regions and uses thereof
|
|
CA2768444A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Rigshospitalet |
Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
|
|
MX355650B
(es)
|
2009-08-11 |
2018-04-26 |
Genentech Inc |
Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
|
|
EP3395832B1
(en)
|
2009-08-20 |
2021-11-24 |
Biosceptre (Aust) Pty Ltd |
Anti p2x7 receptor antibodies and fragments thereof
|
|
WO2011034660A1
(en)
|
2009-09-16 |
2011-03-24 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
AU2010298036B2
(en)
|
2009-09-25 |
2015-05-21 |
Xoma Technology Ltd. |
Screening methods
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
|
WO2011040972A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
EP2496604B1
(en)
*
|
2009-11-06 |
2017-08-23 |
IDEXX Laboratories, Inc. |
Canine anti-cd20 antibodies
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
EP2504032A4
(en)
|
2009-11-24 |
2013-06-19 |
Alderbio Holdings Llc |
IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
|
|
IN2012DN03354A
(cg-RX-API-DMAC7.html)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
EP2516470B1
(en)
|
2009-12-24 |
2018-02-07 |
Biosceptre (Aust) Pty Ltd |
Antibodies to non-functional oligomeric p2x7 receptors
|
|
EP2526421B1
(en)
*
|
2010-01-22 |
2018-11-21 |
Immunomedics, Inc. |
Detection of early-stage pancreatic adenocarcinoma
|
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
|
BR112012022338A2
(pt)
*
|
2010-03-04 |
2017-02-14 |
Vet Therapeutics Inc |
anticorpos monoclonais direcionados a cd20
|
|
EP2542258A4
(en)
*
|
2010-03-04 |
2013-08-21 |
Vet Therapeutics Inc |
ON CD52 MONOCLONAL ANTIBODIES
|
|
US9169329B2
(en)
|
2010-06-01 |
2015-10-27 |
Ludwig Institute For Cancer Research |
Antibodies directed to the receptor tyrosine kinase c-Met
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012031333A1
(en)
|
2010-09-10 |
2012-03-15 |
Biosceptre International Limited |
Companion animal treatments
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012054077A2
(en)
|
2010-10-19 |
2012-04-26 |
Mayo Foundation For Medical Education And Research |
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
|
|
WO2012057765A1
(en)
|
2010-10-28 |
2012-05-03 |
The Board Of Regents Of The University Of Texas System |
Recombinant anti-cd19 monoclonal antibodies
|
|
US8992908B2
(en)
|
2010-11-23 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of oral mucositis
|
|
JP5947807B2
(ja)
*
|
2010-12-14 |
2016-07-06 |
テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark |
ナノ粒子組成物への放射性核種の封入
|
|
EP2675485A4
(en)
|
2011-02-15 |
2014-10-15 |
Immunomedics Inc |
ANTI-MUCIN ANTIBODY FOR THE EARLY RECOGNITION AND TREATMENT OF PANCREATIC CANCER
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
EP2714735B1
(en)
|
2011-06-03 |
2021-07-21 |
XOMA Technology Ltd. |
Antibodies specific for tgf-beta
|
|
WO2013003895A1
(en)
|
2011-07-01 |
2013-01-10 |
Biosceptre International Limited |
Combination therapy
|
|
CA2842195A1
(en)
|
2011-07-18 |
2013-01-24 |
Immunomedics, Inc. |
Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
GB2495113A
(en)
*
|
2011-09-29 |
2013-04-03 |
Bioinvent Int Ab |
Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
US9790280B2
(en)
|
2011-10-26 |
2017-10-17 |
Elanco Tiergesundheit Ag |
Monoclonal canine CD20 antibodies and methods of use
|
|
US9192664B2
(en)
|
2011-12-05 |
2015-11-24 |
Immunomedics, Inc. |
Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
BR112014025898A2
(pt)
|
2012-04-17 |
2017-11-07 |
Mayo Found Medical Education & Res |
anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
MX2014015205A
(es)
|
2012-06-14 |
2015-08-14 |
Ambrx Inc |
Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US20240148873A1
(en)
|
2012-12-13 |
2024-05-09 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
US8877202B2
(en)
|
2013-02-07 |
2014-11-04 |
Immunomedics, Inc. |
Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
|
CN111363047A
(zh)
|
2013-03-12 |
2020-07-03 |
分子模板公司 |
用于引起细胞内化的cd20结合免疫毒素及其使用方法
|
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US9452228B2
(en)
|
2013-04-01 |
2016-09-27 |
Immunomedics, Inc. |
Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
ES2749862T3
(es)
|
2014-01-27 |
2020-03-24 |
Molecular Templates Inc |
Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
|
|
ES2978993T3
(es)
|
2014-02-21 |
2024-09-23 |
Ibc Pharmaceuticals Inc |
Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
JP6417421B2
(ja)
|
2014-02-28 |
2018-11-07 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
荷電連結体及び共役体のためのその使用
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
KR102496206B1
(ko)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
|
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
WO2016073963A1
(en)
|
2014-11-07 |
2016-05-12 |
Mayo Foundation For Medical Education And Research |
Treatment of neonatal hypoxia including impairments or effects thereof
|
|
JP6788586B2
(ja)
|
2014-11-19 |
2020-11-25 |
コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. |
Hnlを用いる診断方法
|
|
WO2016126950A1
(en)
*
|
2015-02-05 |
2016-08-11 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
CN107614515B
(zh)
|
2015-05-28 |
2022-03-22 |
免疫医疗公司 |
用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
|
|
CN114656573B
(zh)
|
2015-05-30 |
2024-09-27 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
EP3307772B1
(en)
|
2015-06-12 |
2020-09-09 |
Ludwig Institute For Cancer Research Limited |
Tgf-beta 3 specific antibodies and methods and uses thereof
|
|
EP3307749A4
(en)
|
2015-06-15 |
2019-06-19 |
Hangzhou Dac Biotech Co., Ltd |
HYDROPHILIC LINKER FOR CONJUGATION
|
|
AU2016282334B2
(en)
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
JP6993958B2
(ja)
|
2015-07-06 |
2022-02-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性抗原結合分子およびその使用
|
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
JP2018532693A
(ja)
|
2015-08-06 |
2018-11-08 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CA3003399A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
|
WO2017083306A1
(en)
|
2015-11-09 |
2017-05-18 |
R.P. Scherer Technologies, Llc |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
WO2017106806A1
(en)
|
2015-12-18 |
2017-06-22 |
Federica Cavallo |
COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
EP4166161B1
(en)
|
2016-04-14 |
2026-03-04 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
|
CN118530358A
(zh)
|
2016-08-01 |
2024-08-23 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
|
US10858428B2
(en)
|
2016-09-28 |
2020-12-08 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
|
KR20220147719A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
MX2019006656A
(es)
|
2016-12-07 |
2019-09-09 |
Molecular Templates Inc |
Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN111010867B
(zh)
|
2017-05-30 |
2023-05-12 |
俄克拉何马大学董事会 |
抗双皮层蛋白样激酶1抗体及其使用方法
|
|
MX2020006010A
(es)
*
|
2017-12-11 |
2020-10-16 |
Triphase Res And Development Iii Corp |
Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
|
|
WO2019143948A1
(en)
|
2018-01-18 |
2019-07-25 |
Fred Hutchinson Cancer Research Center |
Altering inflammatory states of immune cells in vivo by modulating cellular activation states
|
|
KR20200143634A
(ko)
|
2018-04-17 |
2020-12-24 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Her2及び/またはaplp2に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
WO2020053634A1
(en)
*
|
2018-09-16 |
2020-03-19 |
Habibi Anbouhi Mahdi |
Anti-cd22 heavy-chain variable domain antibody
|
|
EP3877055A1
(en)
|
2018-11-05 |
2021-09-15 |
Ludwig Institute for Cancer Research Ltd |
Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
|
|
CA3118027A1
(en)
|
2018-11-05 |
2020-05-14 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
|
|
CA3131705A1
(en)
|
2019-03-27 |
2020-10-01 |
Umc Utrecht Holding B.V. |
Engineered iga antibodies and methods of use
|
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
|
WO2022152282A1
(zh)
*
|
2021-01-18 |
2022-07-21 |
江苏先声药业有限公司 |
抗人cd22的单克隆抗体及其用途
|
|
EP4342497A1
(en)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
WO2022265912A1
(en)
|
2021-06-16 |
2022-12-22 |
Gundersen Lutheran Medical Foundation, Inc. |
Antibodies targeting an amphiregulin-derived cell surface neo-epitope
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
TW202426433A
(zh)
|
2022-09-23 |
2024-07-01 |
瑞士商紐利迪姆股份公司 |
成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
|
|
IL319722A
(en)
|
2022-09-23 |
2025-05-01 |
Nuclidium Ag |
High purity radionuclides and their diagnostic and medical uses
|
|
CN116333035B
(zh)
*
|
2022-12-07 |
2025-05-23 |
复旦大学附属肿瘤医院 |
靶向磷酸化akt蛋白的pet探针及其合成方法与应用
|
|
US12473370B2
(en)
|
2023-10-03 |
2025-11-18 |
Absci Corporation |
TL1A associated antibody compositions and methods of use
|
|
WO2025122885A1
(en)
|
2023-12-08 |
2025-06-12 |
Absci Corporation |
Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
|